24/7 Market News Snapshot 28 May, 2025 – Veru Inc. (NASDAQ:VERU)

May 28, 2025

DENVER, Colo., 28 May, 2025 (www.247marketnews.com) – (NASDAQ:VERU) are discussed in this article.
Veru Inc. is experiencing a notable uptick in pre-market trading, with shares climbing over 18% to reach a price of $0.602, up from $0.509 at the previous close. This surge is characterized by strong investor interest, evidenced by a trading volume of 9.02 million shares, suggesting a potential continuation of this upward trend. Market analysts recommend close monitoring of key resistance levels above $0.60, and support around $0.50, which could serve as critical entry points for traders. Overall, the technical indicators indicate a positive outlook for Veru Inc., presenting a compelling opportunity within the biotech sector.

In a significant development, Veru has also announced promising topline safety results from its Phase 2b QUALITY clinical study, which investigated the combination of enobosarm with semaglutide for weight management in older adults (≥60 years). The study results revealed that the enobosarm 3mg and semaglutide combination boasts a favorable safety profile, with participants reporting fewer gastrointestinal side effects compared to those receiving semaglutide alone. Importantly, no substantial increases in liver injury or obstructive sleep apnea were observed, highlighting enobosarm’s compatibility with established obesity treatments.

Efficacy data from the trial further demonstrated that the enobosarm combination led to a selective reduction in fat mass, with 99% of total weight loss attributed to fat rather than lean mass—an improvement over the typical outcomes associated with semaglutide. Encouraged by these findings, Veru is progressing the enobosarm 3mg dosage into a proposed Phase 3 clinical program and will be engaging with the FDA for regulatory guidance.

As additional efficacy data from an extension study on fat regain prevention is anticipated later this quarter, Veru is fully committed to advancing innovative obesity treatment solutions while preparing to share comprehensive findings at prominent scientific forums.

Related news for (VERU)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.